{
    "clinical_study": {
        "@rank": "48554", 
        "arm_group": {
            "arm_group_label": "Paclitaxel plus trastuzumab", 
            "description": "Patient received paclitaxel plus trastuzumab administered per investigators discretion"
        }, 
        "biospec_descr": {
            "textblock": "fresh tumor tissue and blood samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study is a biospecimen discovery project that will serve as a pilot for a comprehensive\n      'omics approach using fresh core biopsy tissue and blood samples for DNA and protein\n      analysis, as well as paired tumor-normal exome DNA and RNA sequencing."
        }, 
        "brief_title": "NSABP Biospecimen Discovery Project", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted at select NSABP sites where investigators are willing to give\n      paclitaxel plus trastuzumab before the anthracycline-based component of neoadjuvant therapy\n      as a pilot for a comprehensive 'omics approach using next generation sequencing and protein\n      expression and post-translational modification analysis using mass spectrometry (MS) based\n      and Reverse Phase Protein Array-based proteomics.  Tumor samples will be obtained at\n      baseline and 48 to 72 hours after initial drug treatment to study variation in the\n      biological responses to these agents.  The study of tumors both before and early after the\n      first treatment probes the biological responses to treatment and is rich source of\n      predictive biomarkers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core\n             needle biopsy or limited incisional biopsy.\n\n          -  The breast cancer must be HER2-positive based on current ASCO/CAP (American Society\n             of Clinical Oncology/College of American Pathologists) Guideline Recommendations for\n             Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.\n\n          -  The patient must have a mass in the breast measuring greater than or equal to 2.0 cm\n             by physical exam and/or ultrasound that is accessible and safe for repeat biopsy.\n             Patients with a diagnosis of inflammatory breast cancer are eligible if there is a\n             palpable or detectable breast mass that is accessible and safe for repeat biopsy.\n\n          -  Planned initial treatment with a combination of paclitaxel and trastuzumab.  Schedule\n             for paclitaxel/trastuzumab administration is per the investigator.\n\n        Exclusion Criteria:\n\n          -  Excisional biopsy or lumpectomy performed prior to registration.\n\n          -  Previous therapy with chemotherapy or targeted therapy for any malignancy.\n\n          -  Treatment, including radiation therapy (RT), chemotherapy, and/or targeted therapy,\n             administered for the currently diagnosed breast cancer prior to registration.\n\n          -  Other nonmalignant systemic disease that would preclude the patient from receiving\n             chemotherapy and targeted therapy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Women with locally advanced, HER2-positive breast cancer from selected sites in the United\n        States"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850628", 
            "org_study_id": "NSABP DP-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel plus trastuzumab", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Paclitaxel plus trastuzumab", 
                "intervention_name": "trastuzumab", 
                "intervention_type": "Biological", 
                "other_name": "Herceptin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "National Surgical Adjuvant Breast and Bowel Project (NSABP)", 
            "paclitaxel", 
            "trastuzumab", 
            "HER2 positive (human epidermal growth factor receptor 2)", 
            "Proteomics", 
            "Neoadjuvant Therapy", 
            "Anthracycline therapy", 
            "Locally advanced", 
            "Operable", 
            "Biomarkers"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "University of Florida"
                }, 
                "investigator": {
                    "last_name": "Carmen Allegra, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hopital"
                }, 
                "investigator": {
                    "last_name": "Thomas J Doyle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Adel Tabchy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15212"
                    }, 
                    "name": "Allegheny General Hospital"
                }, 
                "investigator": {
                    "last_name": "Thomas Julian, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Magee-Women's Hospital of UPMC"
                }, 
                "investigator": {
                    "last_name": "Adam Brufsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "NSABP Biospecimen Discovery Project", 
        "overall_contact": {
            "email": "diana.gosik@nsabp.org", 
            "last_name": "Diana Gosik, RN, BS", 
            "phone": "412-330-4692"
        }, 
        "overall_official": {
            "affiliation": "NSABP Foundation, Inc.", 
            "last_name": "Norman Wolmark, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure variation in biologic response by comprehensive tumor 'omics profiling in patients receiving an upfront regimen containing paclitaxel plus trastuzumab", 
            "safety_issue": "No", 
            "time_frame": "blood and tissue specimens will be collected at the time of diagnosis; prior to treatment; 48 and 72 hours following first dose of treatment; and following surgery, if tumor remains."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Surgical Adjuvant Breast and Bowel Project (NSABP)", 
        "sponsors": {
            "collaborator": {
                "agency": "Breast Cancer Research Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Surgical Adjuvant Breast and Bowel Project (NSABP)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}